Published in Neurology on June 08, 2010
Will the real multiple sclerosis please stand up? Nat Rev Neurosci (2012) 1.61
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol (2015) 1.05
Cognitive impairment in early stages of multiple sclerosis. Neurol Sci (2010) 1.04
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology (2015) 1.01
Spinal cord MRI in multiple sclerosis--diagnostic, prognostic and clinical value. Nat Rev Neurol (2015) 1.01
The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. PLoS One (2015) 0.94
Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Mult Scler Int (2013) 0.93
Cognition in multiple sclerosis: relevance of lesions, brain atrophy and proton MR spectroscopy. Neurol Sci (2010) 0.93
Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry (2015) 0.90
Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modeling. Neuroimage Clin (2013) 0.90
Optimizing treatment success in multiple sclerosis. J Neurol (2015) 0.90
Cortical atrophy in experimental autoimmune encephalomyelitis: in vivo imaging. Neuroimage (2011) 0.88
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord (2013) 0.87
Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. Nat Rev Neurol (2015) 0.87
Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis. PLoS One (2015) 0.86
Neuroimaging in multiple sclerosis: neurotherapeutic implications. Neurotherapeutics (2011) 0.85
Reliable measurements of brain atrophy in individual patients with multiple sclerosis. Brain Behav (2016) 0.81
Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int (2014) 0.81
Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers (2013) 0.80
The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis. Ther Adv Neurol Disord (2015) 0.80
Brain MRI atrophy quantification in MS: From methods to clinical application. Neurology (2016) 0.78
MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment. J Neurol (2014) 0.78
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine (2017) 0.78
Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence. Ther Adv Neurol Disord (2016) 0.78
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis. CNS Drugs (2016) 0.77
A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. BMC Neurol (2016) 0.77
Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy. Ups J Med Sci (2012) 0.76
Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker. Neuroimage Clin (2015) 0.76
Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis. Neuroimage Clin (2014) 0.76
Sub-millimeter imaging of brain-free water for rapid volume assessment in atrophic brains. Neuroimage (2014) 0.76
Global and regional annual brain volume loss rates in physiological aging. J Neurol (2017) 0.76
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives. Int J Mol Sci (2016) 0.75
Bayesian framework inspired no-reference region-of-interest quality measure for brain MRI images. J Med Imaging (Bellingham) (2017) 0.75
Brain structural changes in women and men during midlife. Neurosci Lett (2016) 0.75
Imag(in)ing multiple sclerosis: Time to take better pictures. J Neuroimmunol (2016) 0.75
Temporal filtering of longitudinal brain magnetic resonance images for consistent segmentation. Neuroimage Clin (2016) 0.75
Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion. Neurology (2016) 0.75
Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis. CNS Drugs (2017) 0.75
The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis. PLoS One (2016) 0.75
Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod. BMC Neurol (2016) 0.75
Lipoic acid in secondary progressive MS: A randomized controlled pilot trial. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
Serum retinol levels are associated with brain volume loss in patients with multiple sclerosis. Mult Scler J Exp Transl Clin (2017) 0.75
Longitudinal MR spectroscopy of neurodegeneration in multiple sclerosis with diffusion of the intra-axonal constituent N-acetylaspartate. Neuroimage Clin (2017) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A (2006) 19.60
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (2010) 11.55
MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol (1987) 8.48
Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol (2007) 7.30
Structural basis of cell-cell adhesion by cadherins. Nature (1995) 6.56
Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell (1991) 6.28
Spectrographic data concerning vitamin A and liver oils. Biochem J (1931) 6.14
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell (1992) 5.29
Reduced resting-state brain activity in the "default network" in normal aging. Cereb Cortex (2007) 5.28
Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet (2001) 5.09
X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science (1999) 4.78
Hydroxyproline arabinosides in the plant kingdom. Plant Physiol (1971) 4.67
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry (1992) 4.16
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology (2010) 3.98
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Altered electrical properties in Drosophila neurons developing without synaptic transmission. J Neurosci (2001) 3.80
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain (2001) 3.51
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'. Trends Parasitol (2006) 3.34
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage (2004) 3.25
Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber's hereditary optic neuropathy. J Med Genet (1989) 3.25
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 3.21
The crystal structure of dimeric kinesin and implications for microtubule-dependent motility. Cell (1997) 3.17
A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci (1993) 3.16
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology (2007) 2.88
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84
Cortical lesions in multiple sclerosis. Brain (1999) 2.83
Incident lacunes influence cognitive decline: the LADIS study. Neurology (2011) 2.81
MR imaging findings in 56 patients with Wernicke encephalopathy: nonalcoholics may differ from alcoholics. AJNR Am J Neuroradiol (2008) 2.76
White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry (2002) 2.72
A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage (2003) 2.67
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.66
Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol (1984) 2.64
Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology (1995) 2.63
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
An activating mutation of AKT2 and human hypoglycemia. Science (2011) 2.60
Structure of a cephalosporin synthase. Nature (1998) 2.59
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol (1993) 2.56
A centralised telephone service for tobacco cessation: the California experience. Tob Control (2000) 2.55
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol (1985) 2.50
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology (2007) 2.47
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Prognostic significance of blood pressure variability after thrombolysis in acute stroke. Neurology (2008) 2.45
EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol (2010) 2.45
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. J Hepatol (2001) 2.42
Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology (2008) 2.41
Antineutrophil cytoplasmic antibodies, cystic fibrosis, and infection. Lancet (1991) 2.41
La Crosse encephalitis in children. N Engl J Med (2001) 2.38
Corticosteroid-induced suppression of the hypothalamo-pituitary-adrenal axis: observations on patients given oral corticosteroids for rheumatoid arthritis. Q J Med (1967) 2.38
The persistent vegetative state. BMJ (1995) 2.35
Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology (2002) 2.34
Management of acute optic neuritis. Lancet (2002) 2.33
Prevalence and severity of microbleeds in a memory clinic setting. Neurology (2006) 2.29
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology (2011) 2.26
Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology (2001) 2.24
Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology (2005) 2.24
Vasopressin administration facilitates fluid removal during hemodialysis. Kidney Int (2006) 2.23
Doppler echocardiographic measurement of low velocity motion of the left ventricular posterior wall. Am J Cardiol (1989) 2.23
Automation of sample mounting for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr (2006) 2.22
Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology (2006) 2.19
The pathophysiology of HOX genes and their role in cancer. J Pathol (2005) 2.18
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 2.17